Plasma angiopoietin-2 levels increase in children following cardiopulmonary bypass
- First Online:
- Cite this article as:
- Giuliano, J.S., Lahni, P.M., Bigham, M.T. et al. Intensive Care Med (2008) 34: 1851. doi:10.1007/s00134-008-1174-9
- 112 Downloads
The aim was to investigate the effects of cardiopulmonary bypass (CPB) on plasma levels of the vascular growth factors, angiopoietin (angpt)-1, angpt-2, and vascular endothelial growth factor (VEGF).
The design was a prospective, clinical investigation.
The setting was a 12-bed pediatric cardiac intensive care unit of a tertiary children’s medical center.
The patients were 48 children (median age, 5 months) undergoing surgical correction or palliation of congenital heart disease who were prospectively enrolled following informed consent.
There were no interventions in this study.
Measurements and results
Plasma samples were obtained at baseline and at 0, 6, and 24 h following CPB. Angpt-1, angpt-2, and VEGF levels were measured via commercial ELISA. Angpt-2 levels increased by 6 h (0.95, IQR 0.43–2.08 ng mL−1 vs. 4.62, IQR 1.16–6.93 ng mL−1, P < 0.05) and remained significantly elevated at 24 h after CPB (1.85, IQR 0.70–2.76 ng mL−1; P < 0.05). Angpt-1 levels remained unchanged immediately after CPB, but were significantly decreased at 24 h after CPB (0.64, IQR 0.40–1.62 ng mL−1 vs. 1.99, IQR 1.23–2.63 ng mL−1, P < 0.05). Angpt-2 levels correlated significantly with cardiac intensive care unit (CICU) length of stay (LOS) and were an independent predictor for CICU LOS on subsequent multivariate analysis.
Angpt-2 appears to be an important biomarker of adverse outcome following CPB in children.